SCHEMBL9945355

SCHEMBL9945355

CC(C)C(O)c1ccc2cc(-c3ccc(F)cc3)ccc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.45
BACE1 P56817 4/20 0.39
ALPL P05186 1/20 0.35
ALPI P09923 1/20 0.35
ALPG P10696 1/20 0.35
PGR P06401 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
MAP4K4 O95819 1/20 0.34
SCN9A Q15858 1/20 0.34
TNIK Q9UKE5 1/20 0.34
APP P05067 2/20 0.33
LRRK2 Q5S007 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9896964 0.74 AAK1 (0.44) AAK1BACE1MAP4K4TNIKMAOA
SCHEMBL9945364 0.72 MAPT (0.37) AAK1APPNPC1RAB9APIK3CA
SCHEMBL9945362 0.72 GRM2 (0.38) AAK1BACE1PGRSCN9ATNIK
SCHEMBL2609295 0.71 BACE1 (0.53) AAK1BACE1ALPLALPIALPG
SCHEMBL4138519 0.71 ALDH1A1 (0.51) BACE1NPC1RAB9A
SCHEMBL12232392 0.70 AAK1 (0.50) AAK1BACE1PDGFRBPDGFRANPC1
SCHEMBL10120019 0.70 AAK1 (0.50) AAK1BACE1NPC1RAB9ADHODH
SCHEMBL9945354 0.70 KMT2A (0.49) NPC1RAB9A
SCHEMBL9946929 0.69 CYP17A1 (0.67) SCN9AMAOB
SCHEMBL10039088 0.69 MAOA (0.57) BACE1MAOAMAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651905-B1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS INC (US) 2017-07-19 EP disclosed
US-8669274-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-03-11 US disclosed
US-8669274-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-03-11 US disclosed
WO-2012082746-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-21 WO disclosed
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149729-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO AAK1 1410/4885BACE1 172/4885ALPL 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.